Polycystic ovary syndrome. Revised diagnostic criteria and long-term health consequences

Eleni Kousta, George Tolis, Stephen Franks

Ippokration Hospital, Athens, Greece (G.T.), Institute of Reproductive & Developmental Biology, Imperial College London, Hammersmith Hospital, London U.K. (S.F.)

ABSTRACT
The diagnostic criteria for polycystic ovary syndrome (PCOS) have recently been revised. The polycystic ovarian morphology has been introduced as part of the criteria and an international consensus has been achieved providing the basis for future research and collaboration. It is now accepted that polycystic ovary syndrome has important long-term health implications, including metabolic disorders and increased risk factors for cardiovascular disease. The overall risk of developing type 2 diabetes among women with PCOS was found to be increased 3-7 times. Women with PCOS have increased levels of cardiovascular risk factors: insulin resistance, obesity, dyslipidaemia, hypertension and markers of abnormal vascular function. However, the level of risk for cardiovascular disease remains uncertain. The limited epidemiological data available to date have shown no increase in cardiovascular events although the incidence of cerebrovascular events was increased. The evidence for an increased risk for endometrial carcinoma among women with PCOS is limited. Long-term epidemiological studies of women with well defined PCOS are needed in order to assess the risk of long-term health consequences, to identify the subgroups among PCOS women who need to be targeted and to determine the timing and nature of measures for intervention and prevention.

Key words: Diagnostic criteria, Long-term health consequences, Polycystic ovary syndrome

INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age, its prevalence varying according to the definition used and the reference population. Although first described almost 70 years ago, there has been no universal agreement about its definition. The most widely accepted definition has been the association of hyperandrogenism with chronic anovulation without specific underlying diseases of the adrenal or pituitary glands. The introduction of modern, high-resolution diagnostic ultrasonography resulted in a morphologically based diagnosis of the syndrome. However, polycystic ovarian morphology based on ultrasound scan was thought to be consistent with the syndrome but not essential for its diagnosis. Recently the European Society for Human Reproduction and Embryology and the
American Society for Reproductive Medicine (ES-HRE/ASRM) formulated a new consensus regarding the definition of PCOS. It is thus now defined as the presence of any two of the following three criteria: (i) polycystic ovaries on ultrasound scan; (ii) oligo-and/or anovulation; and (iii) clinical or biochemical evidence of hyperandrogenism, provided other aetiologies (congenital adrenal hyperplasia, androgen-secreting tumours, Cushing’s syndrome) have been excluded. Furthermore, the ultrasound diagnostic criteria for PCO morphology have been redefined as the presence of 12 or more follicles in each ovary, measuring 2-9 mm in diameter, and/or increased ovarian volume (>10 ml) (Figure 1). It was noted that if only one ovary matches this definition, it is sufficient to define PCO and that this definition does not apply to women on an oral contraceptive. The revised definition for PCOS provides an international framework for the assessment of PCOS and for future research and collaboration.

The clinical and biochemical features of the syndrome are heterogeneous and the combination and degree of expression of these features vary between individuals. In the last few years it has become clear that polycystic ovary syndrome is not simply a combination of hyperandrogenaemia and anovulation but has important long-term health implications. Although disagreement about diagnostic criteria has up to now rendered comparison of epidemiological studies of long-term health risks difficult to achieve, it is now well accepted that PCOS is associated with metabolic disorders (hyperinsulinaemia and insulin resistance, impaired pancreatic β-cell function and increased risk of type 2 diabetes, obesity, hyperlipidaemia) and increased risk factors for cardiovascular disease. In addition, chronic anovulation in women with PCOS is thought to carry an increased risk of endometrial cancer (Table 1).

Diagnostic criteria for the metabolic syndrome among women with PCOS have recently been implemented. The definition requires 3 out of the following 5 criteria: central obesity, hypertriglyceridaemia, low HDL-C, increased blood pressure and hyperglycaemia. These metabolic abnormalities, clustered together, are related to insulin resistance and are important as risk factors for cardiovascular disease and type 2 diabetes among women with PCOS.

In this mini-review, the long-term health consequences for PCOS are also discussed. In order to assess the impact of each individual factor in long-term health, risk factors—metabolic and cardiovascular—are treated separately.

HYPERINSULINAEMIA AND INSULIN RESISTANCE

Insulin resistance is common in the general, normoglycaemic population and varies according to body mass index (BMI) from 10% among lean subjects to 26% or higher among obese subjects. Hypersecretion of insulin is more prevalent than insulin resistance in the obese population as a whole.

Table 1. Long-term health implications of PCOS

<table>
<thead>
<tr>
<th>Metabolic consequences:</th>
</tr>
</thead>
<tbody>
<tr>
<td>– Hyperinsulinaemia and insulin resistance</td>
</tr>
<tr>
<td>– Impaired pancreatic β-cell function and increased risk of type 2 diabetes</td>
</tr>
<tr>
<td>– Obesity</td>
</tr>
<tr>
<td>– Hyperlipidaemia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>General consequences:</th>
</tr>
</thead>
<tbody>
<tr>
<td>– Increased cardiovascular risk factors</td>
</tr>
<tr>
<td>– Endometrial cancer</td>
</tr>
</tbody>
</table>
Definition and long-term consequences of PCOS

(38%)\(^9\). Although insulin resistance is not a disease, its presence in both obese and nonobese subjects is associated with increased risk of cardiovascular morbidity and mortality and type 2 diabetes\(^10\).

There are several reports assessing insulin action among women with PCOS suggesting that women with PCOS have a greater frequency and degree of both hyperinsulinaemia and insulin resistance than age and weight matched controls\(^7,11-15\). Insulin resistance is independent of the effect of obesity; both lean and obese women with PCOS were found to be hyperinsulinaemic and insulin resistant compared to weight matched control subjects, but insulin resistance is more pronounced among obese women with PCOS\(^7,14,16,17\). Insulin resistance among PCOS women was associated with upper body fat distribution\(^18\), while weight reduction in obese PCOS women, especially reduction in abdominal adiposity, resulted in normalisation of insulin sensitivity, suggesting that body fat distribution is an important determinant of insulin resistance in PCOS\(^19\).

Interestingly, insulin resistance is not a feature of all women with PCOS. There are significant differences in insulin sensitivity between ovulatory and anovulatory women with PCOS. Anovulatory women with PCOS display insulin resistance whereas those with a regular menstrual cycle (but who present with symptoms of hyperandrogenism) do not demonstrate insulin resistance\(^20,21\). These observations suggest that there is a strong association between menstrual irregularity and insulin resistance among women with PCOS. Hyperinsulinaemia itself may contribute to the mechanism of anovulation and the expression of PCOS\(^22\). There is no resistance to the steroidogenic action of insulin in the ovaries, although evidence has recently emerged of a selective impairment of insulin-mediated glucose metabolism in the ovary\(^23\). The ovary is therefore exposed and responsive (at least in terms of steroid biosynthesis) to the high circulating levels of insulin. Insulin acts synergistically with LH to stimulate steroidogenesis and to induce premature arrest of the follicle development\(^24\).

Insulin resistance in PCOS has been associated with increased androgen levels, particularly free testosterone (by some but not all authors)\(^7,19,25\). Large doses of testosterone given to healthy female transsexuals can induce insulin resistance\(^26\). However, the interaction between hyperandrogenaemia and the precise aetiology of insulin resistance remain unresolved. Hirsute women with PCOS and hyperandrogenaemia who have regular menstrual cycles present fasting serum insulin concentrations and after-glucose stimulation that are indistinguishable from those in weight matched control subjects and present insulin sensitivity similar to control subjects\(^14,21\). Hyperandrogenaemia does not seem to cause insulin resistance; on the contrary, insulin may affect the expression of androgen by suppressing SHBG and augmenting androgen response to LH\(^7\). These observations suggest that hyperandrogenaemia is not a major determinant of insulin sensitivity in PCOS.

The cause of hyperinsulinaemia among women with PCOS also remains unknown. It may be related to increased insulin receptor serine phosphorylation, which decreases its protein tyrosine kinase activity and leads to a post-binding defect in insulin action and/or abnormal insulin secretion\(^27,19\). It may be that metabolic abnormalities in PCOS start very early in life, during the prenatal or prepubertal period, and an early exposure to androgens during development may affect body fat distribution and insulin action\(^22,28\).

The clinical implication of these observations is that women with PCOS are likely to have insulin resistance and/or hyperinsulinaemia, particularly when they are anovulatory and obese with central fat distribution. Given that insulin resistance is an independent risk factor for metabolic abnormalities, the presence of insulin resistance among PCOS women suggests future risk of cardiovascular disease and type 2 diabetes. Furthermore, using a cardiovascular risk score, insulin resistance in PCOS was found to be an important determinant of cardiovascular risk among women with PCOS independently of obesity\(^16\).

IMPAIRED PANCREATIC B-CELL FUNCTION AND INCREASED RISK OF TYPE 2 DIABETES

Even though the majority of women with PCOS have hyperinsulinaemia and insulin resistance and display increased insulin responses to a glucose load,
studies that carefully assessed β-cell function demonstrate defects in insulin secretion in addition to insulin resistance. Insulin secretory responses to mixed meals in insulin resistant women with PCOS are reduced relative to basal insulin secretion, an abnormality characteristic of type 2 diabetes. Given that when insulin resistance occurs, the β-cell compensates by increasing the secretion of insulin, it is essential to take into account the degree of insulin sensitivity when assessing β-cell function. By using the intravenous glucose tolerance test (IVGTT), both lean and obese women with PCOS had β-cell dysfunction in addition to insulin resistance. The IVGTT has the advantage of estimating the disposition index (insulin sensitivity x acute insulin response to glucose), which allows β-cell function to be interpreted in the light of prevailing insulin resistance and the detection of subtle defects in β-cell function. Defects in β-cell function are more evident among PCOS women who have 1st degree relatives of type 2 diabetes as demonstrated by reduced insulin secretory responses either to bolus (IVGTT) or graded infusions of intravenous glucose and by impairment in the ability to entrain endogenous insulin secretion with glucose. These observations suggest that women with PCOS, even when normoglycaemic, may demonstrate impaired β-cell function on detailed testing. This may be an early metabolic defect contributing to the development of type 2 diabetes later in life. Similar early metabolic changes have also been reported in other groups at high risk for future development of type 2 diabetes, such as normoglycaemic relatives of subjects with type 2 diabetes and/or women with a history of gestational diabetes. Furthermore, recent data suggest that decreased glucose metabolism is present among women with PCOS even when insulin sensitivity and β-cell function are preserved, which may constitute an early feature of disturbed carbohydrate metabolism.

The prevalence of type 2 diabetes has been reported as 3-4% in the general population, increasing up to 10-18% in old age. Several groups have assessed glucose tolerance among PCOS women and the overall risk of developing type 2 diabetes was found to be increased 3-7 times. The figures for prevalence rates of glucose intolerance among women with PCOS are much higher than expected compared with reference populations of women of similar age: 31-35% had IGT and 7.5-10% had type 2 diabetes. Although obesity and age substantially increase the risk, IGT and diabetes are frequent even among non-obese PCOS women (10% and 1.5%, respectively). Apart from obesity and age, waist/hip ratio, family history of type 2 diabetes, and increased androgen concentrations were also associated with glucose intolerance. Oligomenorrhea was found to be a risk factor for the development of type 2 DM and this risk was accentuated, though not totally explained, by obesity.

The risk of glucose intolerance among PCOS women appears to be equally increased in mixed ethnicities of the US population and Asian PCOS groups. However, in a young Mediterranean population with PCOS the prevalence of glucose intolerance was lower than in previous reports (2.5% type 2 diabetes and 16% impaired glucose tolerance), but there were no data for a control group of similar age and ethnicity. In that study environmental factors explaining the lower prevalences of glucose intolerance, such as dietary habits, should be taken into account. In the same study lower birth weight and earlier age of menarche were associated with increased risk for glucose intolerance.

Furthermore, the onset of glucose intolerance in PCOS women seems to occur at an early age, typically in the 3rd-4th decade of life, which is earlier than in the normal population. Abnormalities in both insulin action and secretion and glucose intolerance have been observed even in adolescents with PCOS and in young girls with premature adrenarche (who may go on to develop PCOS in adolescence). The prevalence of glucose intolerance has been reported to be as high as 30-40% among both lean and obese adolescents with PCOS.

An association between gestational diabetes and PCOS has been observed. The prevalence of PCO morphology in women with previous GDM is significantly higher than in control women, suggesting that women with PCO are at risk of developing gestational diabetes. Given that gestational diabetes is a forerunner of type 2 diabetes and the majority of women with gestational diabetes will...
develop type 2 diabetes in later life\textsuperscript{52}, these observations reinforce the hypothesis of increased risk of diabetes in women with PCOS.

A significant percentage of 1\textsuperscript{st} degree relatives of the general population of women with PCOS have defects in insulin action and secretion or type 2 diabetes. In a recent study, a strong family history of type 2 diabetes was noted among parents of women with PCOS: 46\% of the mothers and 58\% of the fathers of women with PCOS had IGT or type 2 diabetes and female family members with normoglycaemia had insulin resistance\textsuperscript{53}. Hyperinsulinaemia was found to be common among female and male 1\textsuperscript{st} degree relatives of women with PCOS\textsuperscript{54}. Evidence for a familial correlation of \(\beta\)-cell dysfunction (strong sibling correlation for the acute insulin secretion and the disposition index), but no insulin resistance, was noted among families of women with PCOS\textsuperscript{55}. In another study, 25\% of the sisters of women with PCOS were affected (having menstrual irregularities and/or hyperandrogenaemia) and had increased insulin levels and decreased glucose/insulin ratios suggestive of insulin resistance, compared to control women\textsuperscript{56}. These observations suggest that abnormalities of glucose regulation and type 2 diabetes are common among relatives of women with PCOS and that there is a strong association between the two diseases.

Women with PCOS have a greater chance of developing glucose intolerance at an earlier age than the general population. This risk is further emphasised by recent epidemiological observations that noted increased mortality from the complications of diabetes among women with PCOS\textsuperscript{60}. Central obesity and family history of type 2 diabetes are parameters influencing the risk, as in the general population. Menstrual irregularity is probably an additional risk factor. Ethnicity does not appear to influence the risk, suggesting that PCOS is a more important risk factor.

**OBESITY**

Obesity is a known independent risk factor for the development of type 2 diabetes and cardiovascular disease. The prevalence of obesity is rising in societies which have adopted a westernised lifestyle and is today a major health issue\textsuperscript{58}. In the general population, hyperinsulinaemia seems to be the main metabolic feature among normoglycaemic normotensive obese subjects, whereas insulin resistance is not as prevalent as previously thought\textsuperscript{9}. Most importantly, cardiovascular morbidity and mortality are increased in obese women independently of other risk factors\textsuperscript{59}.

The association between PCOS and obesity had been noted in early studies on PCOS. The prevalence of obesity among women with PCOS was observed to be as high as 41\% when the diagnosis was based on histological features after wedge resection\textsuperscript{60}. This prevalence varies from country to country, depending on the population studied and the criteria used to define PCOS. According to the UK studies, the prevalence of obesity among PCO women is 35-38\%\textsuperscript{61,62}, whereas it is 36\% in a black and white population in the USA\textsuperscript{2}, 10-38\% in Mediterranean countries\textsuperscript{3,4} and as high as 63\% in Australia where the diagnosis was based on stricter criteria\textsuperscript{63}. Women with PCOS tend to have a central distribution of adiposity\textsuperscript{64,65}. Obesity in adolescence and weight gain after adolescence were associated with PCOS symptoms among women of reproductive age\textsuperscript{66}.

Obesity in women with PCOS has not only long-term implications for the general health of the individual but additionally has important reproductive impacts (Table 2). Obese women with PCOS have a higher prevalence of menstrual disorders and infertility\textsuperscript{61}, are more likely to be hirsute and have lower SHBG levels, leading to higher serum concentrations of free testosterone\textsuperscript{14,61}, than lean women with PCOS. Obese women with PCOS are less likely to respond to induction of ovulation treatment\textsuperscript{67-69}, require larger doses of gonadotropins to achieve

<table>
<thead>
<tr>
<th>Table 2. Reproductive impact of obesity in PCOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>– Increased prevalence of menstrual disorders and hyperandrogenism</td>
</tr>
<tr>
<td>– Reduced response to ovulation induction, requirement for higher doses</td>
</tr>
<tr>
<td>– Increased prevalence of miscarriage</td>
</tr>
<tr>
<td>– Higher prevalence of pregnancy complications - including gestational diabetes</td>
</tr>
</tbody>
</table>
ovulation and pregnancy⁶⁷,⁶⁸ and are more likely to miscarry⁶⁷,⁷⁰,⁷¹. Furthermore, obesity in the overall population is associated with a higher prevalence of fetal abnormalities and more pregnancy complications including a higher risk for gestational diabetes⁷².

Weight loss may, at least partially, reverse the biochemical abnormalities (including insulin resistance, hyperlipidaemia and dyslipidaemia) and improve reproductive function and hirsutism in obese women with PCOS⁵⁹,⁷³,⁷⁴. Weight reduction in obese women with PCOS is encouraged before considering therapy to induce ovulation. Modifying additional lifestyle factors, including alcohol consumption, psychosocial stressors and smoking, are also crucial in the long-term outcome of PCOS⁵⁵.

The factors, other than diet, that contribute to obesity among women with PCOS are unclear. An abnormality in energy expenditure in women with PCOS, notably in postprandial thermogenesis, has been implicated. Postprandial thermogenesis was significantly reduced in women with PCOS and there was a direct correlation of postprandial thermogenesis with insulin resistance⁵⁵. It was calculated that if the difference in energy balance were maintained (as seems likely) over a year, women with PCOS would have an excess of 1.9 kg of fat. It may be that this represented an evolutionary advantage in periods of calorie restriction, but when calorie intake is excessive it may contribute to obesity.

In summary, a significant proportion of women with PCOS are affected by obesity. The cause of obesity among women with PCOS is unknown, but the presence of obesity in PCOS women has important long-term metabolic and reproductive consequences including increased risk for type 2 diabetes, cardiovascular disease, anovulation, infertility and miscarriage. Diet and lifestyle modification may improve reproductive function and fertility.

HYPERLIPIDAEMIA

It is well known that lipid abnormalities are associated with risk for cardiovascular disease. High-density lipoprotein (HDL-C)⁷⁶,⁷⁷, triglyceride levels and low-density lipoproteins (LDL-C) are strong independent predictors of cardiovascular death in women while total cholesterol levels have been shown to be poor predictors of cardiovascular mortality⁷⁷.

Dyslipidaemia is common among women with PCOS. There are several studies reporting higher total cholesterol, LDL-C⁴¹,⁶⁵,⁷⁸,⁷⁹, VLDL-cholesterol⁸⁰,⁸¹, triglycerides⁴¹,⁶⁵,⁷⁹,⁸¹ and lower HDL-cholesterol levels⁶⁵,⁷⁹,⁸⁰,⁸² among women with PCOS compared with control women. Even after controlling for obesity, lipid abnormalities still persist between PCOS and control women⁶⁵,⁷⁹,⁸³. In a large study of young white women with PCOS, increased LDL-C levels were the predominant lipid abnormality independent of obesity⁷⁸. Furthermore, women with PCOS have raised concentrations of small LDL (LDL III) subfractions, considered to be more atherogenic⁸⁴, and increased hepatic lipase activity compared to weight matched control women⁸¹. The difference in lipid profile is stronger at an earlier age and little difference is noted over the age of 40yrs between PCOS and control women, suggesting a higher risk for atherosclerosis at an earlier age⁶⁵,⁷⁹. This may be due to an earlier onset of hormonal disturbances, obesity and intra-abdominal fat distribution among PCOS women or may reflect the LDL-C increase with age among controls.

Lipid abnormalities in PCOS appear to be related to central adiposity⁸¹ and hyperinsulinaemia⁸⁶,⁸⁷ in some but not in all studies⁸⁶. Androgen levels were associated with triglyceride levels but not with other lipids⁷⁸, whereas others found no association between androgen levels and dyslipidaemia⁸¹. Interestingly, it was observed that women with hirsutism and regular cycles do not present dyslipidaemia compared to control women, whereas those with both hirsutism and oligomenorrhea had lower HDL-C and higher triglycerides⁸⁵, suggesting an association between menstrual irregularity and dyslipidaemia.

Paradoxically, in a large study of young white women with PCOS, HDL-C levels were significantly higher even among obese subjects; however, this difference was not significant after adjusting for age, BMI, insulin and other variables⁷⁸. It is unknown whether these increased HDL-C levels confer some protection against cardiovascular disease in young women with PCOS.
The cause of dyslipidaemia among women with PCOS remains unknown. Dyslipidaemia is more pronounced among obese subjects but cannot totally be attributed to obesity. Dyslipidaemia seems to affect women with PCOS at a younger age, thus increasing the risk for atherosclerosis. Known risk factors of dyslipidaemia, such as central adiposity and insulin resistance, may play a significant role, while the role of androgens is still unclear. Women with menstrual irregularities are likely to be those exhibiting more pronounced dyslipidaemia.

PREVALENCE OF OTHER CARDIOVASCULAR RISK FACTORS (TABLE 3)

Hypertension

Data on blood pressure (BP) in women with PCOS are controversial. Blood pressure has been reported to be raised among PCOS women compared with control women, even after adjusting for BMI by some but not all investigators. Obese women with PCOS were found to have increased systolic but not diastolic BP compared to weight matched control women, but there was no difference in BP levels among the non-obese group. Women with oligomenorrhea and hirsutism had both systolic and diastolic BP raised, compared to control women. Existing data however need to be interpreted with caution, while it is noteworthy that even small differences in BP may be of clinical relevance since at a group level a BP difference of 1.5-2 mm Hg could have a large impact on population cardiovascular risk.

Endothelial dysfunction, chronic inflammation and altered vascular function

Endothelial dysfunction is an early event in the process of arterial lesion formation and precedes atherosclerosis. Assessment of endothelial function may be a useful prognostic tool for cardiovascular disease. Endothelial function can be assessed directly by measuring peripheral circulation (flow mediated vasodilatation) or, indirectly, by the use of inflammatory markers.

An initial study on a small number of obese women with PCOS and age matched control women reported no difference in endothelial function assessed as endothelium-dependent and -independent vascular function by brachial artery ultrasound) between the two groups, despite the presence of insulin resistance and hyperandrogenism among PCOS subjects. The authors commented that their findings could be attributed to the protective effects of estrogen exposure and/or HDL cholesterol, which did not differ between the two groups. However, subsequent studies reported impaired endothelial function among women with PCOS. These findings were present even among young, normotensive, non-obese and non-dyslipidaemic women with PCOS, as assessed by flow mediated dilatation on the branchial arteries. Resistance to the vasodilating action of insulin was noted and endothelial dysfunction was associated with obesity, insulin resistance and androgen levels in women with PCOS. In this study, leg blood flow responses to the infrafemoral artery were measured in response to infusions of the endothelium-dependent vasodilator methacholine chloride and to euglycemic hyperinsulinemia. Abnormal vascular compliance suggesting vascular stiffness (assessed by recording pulse wave velocity across the aorta and brachial artery) and functional defect in the vascular action of insulin (studied by wire myography, by measuring the concentration response curve to norepinephrine before and after incubation with insulin) was revealed in obese women with PCOS compared to weight matched control subjects. These findings are consistent with early vascular changes associated with insulin resistance.

Endothelin-1 is a marker for abnormal vascular reactivity, which is postulated to contribute to the atherosclerotic process. Insulin has a stimulating effect on endothelin-1 and it was hypothesised that interaction could play a significant role in the development of atherosclerotic lesions in hyperin-

<table>
<thead>
<tr>
<th>Table 3. Cardiovascular risk factors in women with PCOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Insulin resistance</td>
</tr>
<tr>
<td>- Obesity</td>
</tr>
<tr>
<td>- Hyperlipidaemia</td>
</tr>
<tr>
<td>- Hypertension</td>
</tr>
<tr>
<td>- Endothelial dysfunction and chronic vascular inflamma tion</td>
</tr>
<tr>
<td>- Increased vascular thickness</td>
</tr>
</tbody>
</table>
sulinemic conditions. Endothelin-1 is elevated in patients with atherosclerosis, diabetes and obesity. Endothelin-1 was found to be raised in women with PCOS, independently of obesity, suggesting an early vascular impairment.

Chronic inflammation results in endothelial dysfunction and facilitates the initiation of an atherosclerotic process. Several studies suggest that low grade inflammation, reflected by elevated C-reactive protein (CRP), can contribute to the development of arteriosclerosis. CRP is considered not only an inflammatory marker of atherosclerosis but also a mediator of the disease because it contributes to the pathogenesis of lesion formation by interacting with the endothelium and therefore CRP can be seen as a measure of endothelial dysfunction. CRP can independently predict type 2 diabetes and has been linked to insulin resistance. However, the role of inflammation in the etiology of cardiovascular disease (CVD) and other metabolic diseases is still disputed and is not generally accepted.

CRP concentrations were significantly increased in women with PCOS compared to BMI matched control women, and correlated positively with the degree of obesity and inversely with insulin sensitivity, although not with total testosterone concentrations. In another study, CRP levels were higher among women with oligomenorrhea and/or hirsutism than in control women, but after stratification by BMI the differences did not persist.

**Premature atherosclerosis**

Greater carotid intima-media thickness, suggestive of an increased risk for atherosclerosis, was shown in a small number of women with PCOS over 40 years of age, though there was no significant difference in the prevalence of carotid plaque between women with PCOS and controls. When the study was extended to a larger group of white women, the difference in mean carotid IMT between PCOS women and controls, after adjustment for age and BMI, was only noted in women ≥45 years, but not in the younger group (aged 30-44 years). Central obesity was associated with greater extent of carotid IMT among PCOS. Furthermore, the overall group of PCOS women had an increased prevalence of carotid plaque compared to control women.

Subsequent studies confirmed the increase in IMT among young PCOS women compared to age and BMI matched control subjects.

Recently, obese premenopausal PCOS women (aged 30-45 years) were shown to have a greater prevalence and extent of coronary artery calcium, a marker for coronary atherosclerosis measured by electron beam computed tomography, than anticipated. However, it may be that central obesity and dyslipidaemia, present in that group of women with PCOS, contributed to the increased risk for atherosclerosis. Also, the presence of PCO (on ultrasound scan) was associated with more extensive coronary artery disease among a mixed population of pre- and post-menopausal women (all younger than 60 years, with a mean age of 54 and 52 years among women with normal and PCO ovaries, respectively) who had coronary angiography.

These observations suggest that women with PCOS display altered endothelial function, low grade chronic vascular inflammation and increased vascular thickness. These abnormalities are indicative of the early stages of atherosclerosis and therefore suggest an increased risk of atherosclerosis at an earlier age than expected. It is not known whether the cause of these abnormalities can be attributed to PCOS per se or to the metabolic disturbances of the syndrome.

**CARDIOVASCULAR EVENTS**

It has been predicted, based on a risk factor model—taking into account risk factor variables and comparing them with a reference population—that the risk of developing myocardial infarction is considerably increased (relative risk of 7.4) for women with PCOS compared to age matched control women.

Although cardiovascular risk factors are increased among women with PCOS, increased prevalence of cardiovascular events has not been confirmed. In a large retrospective study of 786 women with PCOS in the UK, mortality and morbidity rates from cardiovascular disease were not higher than anticipated. The diagnosis of PCOS was made on ovarian histopathology; the majority of these women had undergone wedge resection about 30 years
Table 4. Assessment of endothelial function in women with PCOS - tests of peripheral circulation and inflammatory markers

<table>
<thead>
<tr>
<th>Authors</th>
<th>Subjects</th>
<th>Age (years)</th>
<th>Method</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mather et al (JCEM) 2000</td>
<td>18 obese PCOS, 19 controls</td>
<td>32</td>
<td>Assessment of endothelium dependent and independent (response to nitroglycerin) vascular reactivity using brachial artery ultrasound</td>
<td>No difference between groups</td>
</tr>
<tr>
<td>Paradisi et al 2001</td>
<td>12 obese PCOS, 13 obese controls</td>
<td>PCOS: 29 controls: 35</td>
<td>Assessment of endothelium dependent vasodilation by measuring leg blood flow responses to intrafemoral artery infusions of methacholine chloride and to euglycemic hyperinsulinaemia</td>
<td>Approximately 50% reduction in endothelium dependent vasodilation and resistance to the vasodilating action of insulin among women with PCOS</td>
</tr>
<tr>
<td>Diamanti-Kandarakis et al 2001</td>
<td>43 PCOS (23 obese and 20 nonobese), 17 controls (7 obese and 10 nonobese)</td>
<td>23</td>
<td>Measurement of endothelin-1</td>
<td>Significantly higher endothelin-1 levels among both lean and obese women with PCOS</td>
</tr>
<tr>
<td>Kelly et al 2001</td>
<td>17 PCOS (mean BMI 31.5 kg/m²), 15 controls (mean BMI 30.3 kg/m²)</td>
<td>PCOS: 26 controls: 33</td>
<td>Measurement of CRP levels</td>
<td>Significantly higher CRP levels among women with PCOS</td>
</tr>
<tr>
<td>Taponen et al 2004</td>
<td>518 cases with oligomenorrhea/and/or hirsutism (mean BMI 25.1 kg/m²), 1036 controls (mean BMI 24.2 kg/m²)</td>
<td>31</td>
<td>Measurement of CRP levels</td>
<td>Significantly higher CPR levels among cases, after stratification for BMI differences are lost</td>
</tr>
<tr>
<td>Orio et al 2004</td>
<td>30 PCOS, 30 controls</td>
<td>22</td>
<td>Assessment of endothelium dependent vascular reactivity using brachial artery ultrasound. Measurement of endothelin-1</td>
<td>Significantly decreased flow mediated-dilation and significantly higher endothelin-1 levels among women with PCOS.</td>
</tr>
<tr>
<td>Tarkun et al 2004</td>
<td>37 PCOS (mean BMI 23.8 kg/m²), 25 controls (mean BMI 22.9 kg/m²)</td>
<td>PCOS: 23 controls: 24</td>
<td>Assessment of endothelium dependent and independent (response to nitroglycerin) vascular reactivity using brachial artery ultrasound. Measurement of CRP levels</td>
<td>Significantly decreased flow and nitroglycerin mediated- (endothelium dependent and independent) dilation and significantly higher CRP levels among women with PCOS</td>
</tr>
</tbody>
</table>

before the follow-up study. Observed death rates were compared with expected deaths using standardized mortality rates. There was an increased number of deaths where type 2 diabetes was a complicating factor. A more detailed subsequent study by the same research group showed that cardiovascular morbidity and mortality in women with PCOS were similar to those in the general population.

Although the history of coronary heart disease was not more common among women with PCOS, the history of cerebrovascular disease was increased. Women with PCOS had higher levels of several cardiovascular and metabolic risk factors such as diabetes, hypertension, hypercholesterolaemia, hypertriglyceridaemia and increased waist/hip ratio. After adjusting for BMI the differences for diabetes,
hypertension and hypercholesterolaemia remained significant. An increased prevalence of family history for type 2 diabetes was also noted.

Given the increased prevalence of cardiovascular and metabolic risk factors among women with PCOS, it is perhaps surprising that there was no significant increase in the prevalence of cardiovascular events. Subjects studied were middle-aged at the time of observation (the mean age in the Wild et al study was 57 years), and the prevalence of cardiovascular events in both study and reference groups was low. It may be that, as the cohort ages, there will be a divergence between PCO and control groups in the incidence of coronary heart disease. Moreover, these subjects were recruited mostly through their recorded treatment by ovarian wedge resection. This treatment is known to have short-term benefits for PCOS but, although unlikely, long-term benefits in terms of cardiovascular health in those women cannot be excluded. On the other hand, those women with PCOS who underwent wedge resection are likely to be those with the more severe symptoms of the syndrome. Nevertheless, irrespective of any effect of surgical intervention, the presence of a protective factor against cardiovascular disease related to PCOS cannot be excluded. Further long-term epidemiological studies are needed before definite conclusions can be drawn. In the meantime, it seems sensible to counsel patients “at risk” (i.e. particularly obese, anovulatory women with PCOS) about possible long-term risk of cardiovascular disease and to implement dietary and lifestyle changes where appropriate.

ENDOMETRIAL CANCER

An association between PCOS and endometrial carcinoma was first suggested in 1949, 14 years after the original description of the syndrome. Women with PCOS have been thought to be at increased risk for endometrial cancer through chronic anovulation and unopposed estrogen exposure of the endometrium. However, the evidence for such an association in epidemiological studies is incomplete and contradictory. Many studies providing evidence of an increased risk of endometrial cancer in women with PCOS do not provide an estimate of the relative risk compared with the general population, or when the observations were compared to control women the numbers of the subjects were small.

The risk of developing endometrial cancer has been shown to be influenced by a number of factors including long-term exposure to unopposed estrogens, obesity, nulliparity and infertility. Women with anovulatory infertility were found to be at risk of developing endometrial hyperplasia and, in some cases, this will be atypical and therefore premalignant. In one of these studies it was noted that the risk for endometrial carcinoma was increased only among the obese subgroup of anovulatory women. Although most, but not all, of the women with chronic anovulation have PCOS, and additionally not all women with PCOS have anovulation, the risk for endometrial carcinoma based on anovulatory subjects cannot be applied to all women with PCOS.

Obese women in the general population are at increased risk for endometrial cancer compared to normal weight women, and hypertension and relative hyperglycaemia were found to be significant markers of risk. Women with types 1 and 2 diabetes mellitus have also been shown to be at increased risk for endometrial cancer. It needs to be borne in mind that the apparent association between PCOS and endometrial carcinoma may be related to metabolic abnormalities arising as a result of the syndrome. In a retrospective study of 345 women with PCOS, analysing the various causes of morbidity and mortality, a significant risk of endometrial carcinoma was observed among PCOS women (OR 5.3), but obesity could be a confounding factor.

There are no prospective studies demonstrating increased risk for endometrial carcinoma among women with PCOS. PCOS is associated with risk factors for endometrial cancer, but it has not yet been clarified whether the incidence or mortality from endometrial cancer among PCOS is increased. It is likely that obese women with PCOS and oligomenorrhea or amenorrhea are at greater risk. Due to limited data, universal screening or preventive strategies for these women cannot be applied at present but in order to prevent endometrial hyperplasia it
Definition and long-term consequences of PCOS

has been considered important to shed the endometrium by inducing withdrawal bleed at least every 3 months among women with PCOS who have oligomenorrhea or amenorrhea.

SUMMARY

The overall risk of the development of type 2 diabetes was found to be increased 3-7 times among women with PCOS. Women with PCOS have several risk factors for developing type 2 diabetes including central obesity, abnormalities in insulin action and secretion and a family history of type 2 diabetes. Menstrual irregularity may be an additional risk factor. Furthermore, mortality from the complications of diabetes is increased among women with PCOS.

Women with PCOS have increased levels of cardiovascular risk factors: insulin resistance, obesity, dyslipidaemia, hypertension and markers of abnormal vascular function. This adverse cardiovascular risk profile may start at an early age and may lead to premature atherosclerosis. However, the level of risk of cardiovascular disease is uncertain. The limited epidemiological data available to date have shown no increase in cardiovascular events, although the incidence of cerebrovascular events was increased.

Women with PCOS are predisposed to obesity. Obesity is an important independent risk factor for cardiovascular disease and type 2 diabetes. The presence of obesity in PCOS women has not only long-term metabolic health consequences but also important reproductive consequences including anovulation, infertility and miscarriage. Diet and lifestyle modification may improve reproductive function and fertility.

Women with PCOS have been thought to have increased risk for endometrial carcinoma, through anovulation and increased exposure to unopposed estrogen; however, epidemiological data to support this hypothesis is limited. Among the overall group of women with PCOS, those who have the greater prevalence of cardiovascular risk factors and are at higher risk for type 2 diabetes and endometrial carcinoma are those who are anovulatory and obese.

The new consensus regarding the definition of PCOS provides an international framework for the clinical assessment of PCOS and for future research and collaboration. Importantly, there are as yet no large, long-term studies of women with well defined PCOS that will allow clear assessment of the risk of disease in later life. Such epidemiological studies are needed to assess the risk of long-term health consequences, to identify the subgroups among PCOS women which need to be targeted and to determine the timing and nature of measures for intervention and prevention.

REFERENCES

10. Reaven G, 2002 Metabolic syndrome: pathophysiolo-


Definition and long-term consequences of PCOS


111. Franks S, 2001 Are women with polycystic ovary syndrome at increased risk of cardiovascular disease? Too early to be sure, but not too early to act! Am J Med 111: 665-666.


